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Introduction
Melanoma remains the leading cause of skin cancer–related 
deaths, and an estimated 76 380 individuals will be diagnosed 
in the United States in 2016.1 Early-stage disease has a favora-
ble prognosis with surgical intervention as the mainstay of 
treatment. The survival rate of individuals with stage I and 
stage II disease is 53% to 97%, whereas involvement of regional 
lymph nodes (stage III) results in a 5-year survival of 40% to 
78%.2 Not surprisingly, distant metastatic disease has the worst 
prognosis with a survival rate of just 33% to 62%.2 Adjuvant 
therapies with targeted molecular and immunotherapies have 
been investigated in individuals with locally advanced disease; 
however, recurrence rates are high.3 Eggermont et  al4 found 
that treatment of stage III melanoma with the anti-Cytotoxic 
T-Lymphocyte Associated Protein 4 (CTLA-4) drug, ipili-
mumab, resulted in a recurrence-free survival of 46.5% at 
3 years. Unfortunately, in the setting of metastatic disease, 
many individuals with a primary therapeutic response to 
immune-based agents will often develop recurrence despite 
initial disappearance of most or all of their disease.5
MicroRNAs (miRs) consist of 19 to 22 nucleotides, non-
coding RNA molecules present within all cells. MicroRNAs 
target complementary segments on the 3′ untranslated region 
of messenger RNA and result in silencing of translation. More 
than 800 different miRs are present within cells, and the 
expression of miRs differs across tissues and disease processes. 
Dysregulated miRs are involved in several key cellular path-
ways responsible for malignant progression including cellular 
invasion, migration, proliferation, angiogenesis, replicative 
immortality, immune evasion, and avoidance of senescence and 
apoptosis.6 Consequently, miRs have been investigated in vari-
ous malignancies including melanoma.7 MicroRNA dysregu-
lation has been found across different stages of melanoma and 
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ABSTRACT: Melanoma remains the leading cause of skin cancer–related deaths. Surgical resection and adjuvant therapies can result in 
disease-free intervals for stage III and stage IV disease; however, recurrence is common. Understanding microRNA (miR) dynamics following 
surgical resection of melanomas is critical to accurately interpret miR changes suggestive of melanoma recurrence. Plasma of 6 patients with 
stage III (n = 2) and stage IV (n = 4) melanoma was evaluated using the NanoString platform to determine pre- and postsurgical miR expression 
profiles, enabling analysis of more than 800 miRs simultaneously in 12 samples. Principal component analysis detected underlying patterns of 
miR expression between pre- vs postsurgical patients. Group A contained 3 of 4 patients with stage IV disease (pre- and postsurgical samples) 
and 2 patients with stage III disease (postsurgical samples only). The corresponding preoperative samples to both individuals with stage III 
disease were contained in group B along with 1 individual with stage IV disease (pre- and postsurgical samples). Group A was distinguished 
from group B by statistically significant analysis of variance changes in miR expression (P < .0001). This analysis revealed that group A vs 
group B had downregulation of let-7b-5p, miR-520f, miR-720, miR-4454, miR-21-5p, miR-22-3p, miR-151a-3p, miR-378e, and miR-1283 and 
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Changes in miR expression were not readily evident in individuals with distant metastatic disease (stage IV) as these individuals may have 
prolonged inflammatory responses. Thus, inflammatory-driven miRs coinciding with tumor-derived miRs can blunt anticipated changes in 
expression profiles following surgical resection.
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has been implicated as a biomarker with potential diagnostic 
and prognostic usefulness.8 Investigation into its usefulness for 
prediction of recurrence has also been studied.9
Understanding miR dynamics following surgical resection 
of melanoma is incompletely understood yet is necessary to 
accurately interpret miR patterns suggestive of recurrence. 
MiR-210 has been suggested as a marker of early metastatic 
recurrence in melanoma.10 However, evaluation of a single miR 
carries the possibility of overlooking potentially meaningful 
candidates; thus, global investigation of the miR transcriptome 
is more useful. Ferracin et al11 have used microarray and small 
RNA sequencing techniques for postoperative analysis of 
serum and plasma melanoma patient samples. They found dys-
regulation of miR-181a-5p and miR-320a following surgical 
resection. However, staging of melanomas in the aforemen-
tioned study was not specified. Modern approaches such as 
NanoString allow for analysis of the miR transcriptome yet 
require lower starting amounts of RNA and have lower associ-
ated costs compared with microarray.12 Thus, NanoString is 
well suited for noninvasive detection of miRs using plasma 
blood samples where RNA quantities are often miniscule. 
Herein, we perform an exploratory study to evaluate the poten-
tial usefulness of miRs in plasma samples of metastatic mela-
noma following surgical resection. This work highlights the 
similarities of neoplastic and inflammatory-related miRs, 
which may act as a confounding variable in the interpretation 
of plasma miR studies of metastatic melanoma. Thus, future 




Six patients undergoing surgical resection for malignant mela-
noma with metastatic progression to regional lymph node 
basins or distant metastatic sites were selected. These patients 
were tested between 2013 and 2015 at The Ohio State 
University Wexner Medical Center under the auspices of insti-
tutional review board protocol No. 1999C0348. Peripheral 
venous blood collection was performed in EDTA collection 
tubes prior to surgical therapy and on postoperative follow-up 
to 3 weeks after surgery. Peripheral blood samples were centri-
fuged at 1700 rpm for 11 minutes. The plasma layer was iso-
lated and stored at −80°C.
Isolation of RNA
RNA isolation was carried out using 200 µL of plasma samples 
with the miRNeasy mini kit (Qiagen, Hilden, Germany) 
according to the manufacturer’s recommendations. The addi-
tion of 3 miR spike-ins with known concentrations was used as 
loading controls. Additional RNA purification was performed 
using Amicon (Millipore, Billerica, Massachusetts) 0.5-mL 
3-kDa column as per the manufacturer’s recommendations. 
Isolated RNA was stored at −80°C.
NanoString
Three microliters of isolated RNA was loaded onto 
NanoString nCounter (NanoString Technologies, Seattle, 
Washington) platform, and miR quantification was carried 
out as previously described.13 Briefly, miRs were ligated with 
DNA tags to normalize melting temperatures and provide 
unique identification of each miR. Excess tags were removed, 
and a panel of capture and reporter probes containing unique 
fluorescent signals corresponding to individual miRs were 
hybridized at 64°C for 18 hours. Immobilization of hybrid-
ized probes onto a streptavidin-coated cartridge was per-
formed using nCounter Prep Station (NanoString 
Technologies). The fluorescence of each hybridized miR was 
measured by an nCounter Digital analyzer (NanoString 
Technologies) with a high-density scan containing 600 fields 
of view. The investigation included 5 negative and 5 positive 
controls as well as 5 housekeeping genes.
Data analysis
To control for technology-based experimental error, technical 
normalization was applied to the raw expression data of 800 
miRs before log transformation. Technical normalization con-
trols for performance-based experimental error, and it is applied 
to the raw data by the NanoString company. We cannot inde-
pendently verify the algorithm used in the technical normali-
zation. However, it is standard practice and advised by the 
company to utilize technical normalized data rather than the 
raw expression. No miR filtering was applied. Using JMP 10 
software, variables with highest variance were determined 
using the principal component analysis (PCA).
Results
Plasma miR expression of 6 patients undergoing surgical 
resection for melanoma was measured preoperatively and 
postoperatively using a NanoString platform. Two patients 
were diagnosed with stage III disease (patients 2, 3), whereas 
the remaining 4 patients had stage IV disease (patients 1, 4, 5, 
6; Table 1). Notably, standard analysis (t test) of pre- and post-
surgical miR expression data did not reveal any statistically 
significant changes in miR expression. Consequently, PCA 
was used in an exploratory manner to identify potentially 
meaningful associations. This approach mathematically trans-
forms a number of possibly correlated variables into a smaller 
number of uncorrelated variables termed principal components. 
PCA reduces a complex data set to a limited quantity of new 
variables (components) according to variation within the data 
set. The variable with the greatest variation is deemed the 
principle component. PCA is an exploratory analysis method 
that emphasizes variation to bring out strong patterns in com-
plex data sets by reducing their dimensionality. Accordingly, 
using NanoString miR expression data from pre- and postsur-
gical melanoma samples, PCA allows for categorization of 
correlated patterns of miR expression variation (ie, principal 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4 Bioinformatics and Biology Insights 
components) and identification of miRs exhibiting variation 
across the identified components.
Two categories (groups A and B) became evident when 
analyzed through PCA (Figure 1). Two individuals (patients 
2 and 3) did have preoperative and postoperative samples in 
separate groups as defined by PCA. Both of these patients 
had stage IIIc disease. However, this pattern was not observed 
in the remaining individuals with stage IV disease. Three of 
4 individuals with stage IV disease had both preoperative 
and postoperative samples in group A, whereas the remain-
ing patient had both samples in group B. Overall, individuals 
with high variability in miR patterns following surgical 
resection corresponded to individuals with IIIc disease, 
whereas others with distant metastatic disease (stage IV) had 
less variability.
Principal component analysis was performed using multiple 
stratifications. The dominant stratification (component 1) con-
tained the most variability among the samples (74.3%). 
Additional groupings accounted for some variation but to a 
lesser extent (Figure 2). Component 2 contained the second 
highest variability among the sample set followed by the 
remaining components in a sequentially lower degree. Overall, 
the majority of variability within the data set was explained by 
component 1.
Individual miR expression between groups A and B was 
analyzed using analysis of variance (ANOVA), and several 
miRs were differentially expressed to a significant degree (P < 
.0001). This analysis revealed that group A vs group B had 
downregulation of let-7b-5p, miR-520f, miR-720, miR-
4454, miR-21-5p, miR-22-3p, miR-151a-3p, miR-378e, and 
miR-1283 and upregulation of miR-126-3p, miR-223-3p, 
miR-451a, let-7a-5p, let-7g-5p miR-15b-5p, miR-16-5p, 
miR-20a-5p, miR-20b-5p, miR-23a-3p, miR-26a-5p, miR-
106a-5p, miR-17-5p, miR-130a-3p, miR-142-3p, miR-
150-5p, miR-191-5p, miR-199a-3p, miR-199b-3p, and 
miR-1976 (Table 2).
Figure 1. Principal component analysis of plasma miR expression 
following resection of melanoma.
MicroRNA (miR) expression was measured in 6 patients preoperatively 
() and postoperatively () using the NanoString platform. Relationship 
of plasma miR expression before and after surgical resection was  
investigated using principal component analysis according to  
components that could explain the largest variation within the data set. 
Components 1 and 2 account for the largest variation and were used for 
generation of the score plot.
Figure 2. Components contributing to total variation in principal component analysis.
Principal component analysis of microRNA expression in pre- and postsurgical melanoma samples revealed that several components contribute to 
overall variation within the data set. Component 1 contributes to the largest variation.
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Discussion
Exploratory evaluation of miR profiles in plasma of melanoma 
patients before and after surgery did not yield any significant 
miRs (data not shown). However, PCA was able to distinguish 
the 2 groups across all plasma samples, group A and group B, as 
shown in Figure 1. Through the analysis of the miRs that com-
prise component 1 of the PCA analysis, we determined that 
group A vs group B had downregulation of let-7b-5p, miR-520f, 
miR-720, miR-4454, miR-21-5p, miR-22-3p, miR-151a-3p, 
miR-378e, and miR-1283 and upregulation of miR-126-3p, 
miR-223-3p, miR-451a, let-7a-5p, let-7g-5p miR-15b-5p, 
miR-16-5p, miR-20a-5p, miR-20b-5p, miR-23a-3p, miR-
26a-5p, miR-106a-5p, miR-17-5p, miR-130a-3p, miR-142-3p, 
miR-150-5p, miR-191-5p, miR-199a-3p, miR-199b-3p, and 
miR-1976 (P < .0001 using ANOVA). Given the absence of 
technical replicates and normalized controls, this form of data 
driven cohort discovery seemed a sensible approach to elucidate 
potential underlying relationships.
Several of the 5 most differentially expressed miRs in this 
study have been previously reported in the setting of mela-
noma. Both miR-150 overexpression and downregulation have 
been described in malignant melanoma and may exert effects 
on several pathways such as cellular proliferation through regu-
lation of v-myb avian myeloblastosis viral oncogene homolog.14 
MiR-126 is downregulated in malignant melanoma relative to 
primary melanoma cells and leads to increased chemotaxis and 
cellular proliferation in A375M melanoma cells transfected 
with anti-miR-126.15 This effect is mediated in part through 
Table 2. Differential microRNA expression between groups A and B in principal component analysis.
MICRORNA gROUP A AvERAgE gROUP B AvERAgE FOLD CHANgE
hsa-miR-1976 1.509 3.242 2.148
hsa-miR-191-5p 1.639 2.867 1.750
hsa-miR-150-5p 1.498 2.560 1.709
hsa-let-7a-5p 1.832 3.112 1.699
hsa-miR-126-3p 2.147 3.422 1.593
hsa-miR-16-5p 1.924 3.002 1.561
hsa-miR-20a-5p + hsa-miR-20b-5p 2.059 2.942 1.429
hsa-miR-451a 2.827 3.941 1.394
hsa-miR-106a-5p + hsa-miR-17-5p 2.130 2.940 1.380
hsa-miR-142-3p 2.386 3.286 1.377
hsa-miR-15b-5p 2.327 3.039 1.306
hsa-let-7g-5p 2.532 3.223 1.273
hsa-miR-199a-5p 2.048 2.535 1.238
hsa-miR-223-3p 3.536 4.146 1.173
hsa-miR-15a-5p 2.139 2.461 1.150
hsa-miR-23a-3p 2.830 3.112 1.100
hsa-miR-130a-3p 2.774 2.959 1.067
hsa-miR-4454 4.273 4.049 0.948
hsa-miR-21-5p 3.198 2.968 0.928
hsa-let-7b-5p 3.477 3.085 0.887
hsa-let-7c 2.216 1.781 0.803
hsa-miR-199b-5p 1.237 0.961 0.777
hsa-miR-378e 3.383 2.613 0.772
hsa-miR-720 3.668 2.644 0.721
hsa-miR-1283 3.557 2.503 0.704
Differences in individual microRNA expression between groups A and B based on principal component analysis.
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reduced inhibition of miR-126–targeted metalloproteases: a 
disintegrin and metalloprotease domain 9 and matrix metallo-
protease-7.15 Let-7a is downregulated in malignant melanoma 
relative to primary melanoma cell lines, which results in induc-
tion of integrin β3 and increased invasive capacity as assessed 
by Boyden Chamber invasion assays.16 MiR-191 downregula-
tion has been described in association with melanoma patients 
containing BRAF mutations.17 Notably, miR-1976 was the 
most differentially expressed miR; however, it has not been 
previously described in the setting of malignant melanoma.
Among the downregulated miRs, several turned out to be 
known oncomiRs, including miR-21. MiR-21 upregulation 
in malignant melanoma relative to benign nevi has previously 
been shown.7 MiR-21 upregulation in melanoma leads to 
downregulation of tissue inhibitor of metalloprotease-3, 
which in turn leads to increased cellular invasion, thereby 
suggesting a mechanism of miR-21–mediated tumor pro-
gression.8 Furthermore, miR-720 has previously been shown 
to be upregulated in cutaneous melanoma compare with 
benign melanocytic nevi.18
Conversely, there was upregulation of several important 
miRs between group A vs group B. Several of these miRs are 
tumor suppressors that are downregulated in malignant mela-
noma and might be expected to increase following surgical 
excision. For instance, miR-26a-5p downregulation has been 
reported in primary cutaneous melanoma tissue relative to nevi 
and is responsible for inhibition of alpha-type platelet-derived 
growth factor receptor that can lead to increased cellular 
proliferation.19,20
Unlike patients with stage IIIc disease, clear differences in 
miR expression were not observed in plasma samples of pre- 
and postsurgical patients with distant metastatic (stage IV) 
disease. Greater degrees of inflammation have been associ-
ated with later stages of melanoma.21 Bernardes et  al21 
revealed that increased proinflammatory markers such as 
C-reactive protein, γ-glutamyl transpeptidase and malondial-
dehyde (MDA) were present in later stages of melanoma. 
In addition, high levels of MDA persist following surgical 
resection and suggest a sustained inflammatory response.21 
As such, inflammatory miRs associated with postoperative 
wound healing and remodeling may blunt large differences 
across the pre- and postsurgical samples in melanoma 
patients. Indeed, the oncomiR miR-21 can be induced by 
interleukin 6, an important mediator in wound healing.22,23 
Furthermore, angiogenesis is an important component of 
wound healing, and miRs can regulate several proteins 
involved with both angiogenesis and tumor progression, 
including vascular endothelial growth factor (VEGF) (miR-
20a) and Sprouty-related EVH1 domain-containing protein 
1 (SPRED1) (miR-126).24,25 Thus, miRs implicated in onco-
genesis may also participate in the postoperative inflamma-
tory response, thereby blunting anticipated changes following 
surgical excision for distant metastatic lesions.
Fitting with this presumption, 1 patient with stage IV 
disease who underwent a lymphadenectomy had cellulitis 
postoperatively (patient 1) and did not have a major reduction 
in global miR expression. Tili et  al26 report upregulation of 
miR-155 not only in solid and hematologic malignancies but 
also during the inflammatory response, particularly during pro-
liferation of lymphocytes where miR-155 can in turn regulate 
expansion of granulocytes and monocytes, T-cell differentia-
tion, and B-cell maturation. Igglezou et  al27 similarly found 
transient upregulation of miR-155 in postoperative blood sam-
ples following mastectomy. Our results suggest postoperative 
blood draws within weeks of surgical resection for miR analysis 
may not be suitable for proper evaluation of tumor-driven miR 
changes in stage IV patients, given the overlap of miRs involved 
with inflammation and tumor progression.
There are some notable limitations to this study. First, a lim-
ited patient sample of pre- and postsurgical patients was stud-
ied due to the difficulty in obtaining consent from patients 
who were embarking on surgery with the hopes of achieving no 
evidence of disease. This was an exploratory study, and ulti-
mately, greater numbers of patients will be needed in future 
studies to adequately evaluate these findings as well as any 
potential differences. Second, nonsurgical controls were absent; 
however, this was acceptable given the intent to address changes 
within miR profiles between patients before and after surgery. 
These factors limit the power of this analysis and strength of 
our conclusions. The PCA analysis used herein identified miRs 
with a high degree of variance. Additional work is warranted to 
better understand changes in miR expression after surgery and 
validate the significance of the miRs herein.
Conclusions
We suggest miR analysis of plasma in melanoma patients is 
feasible to analyze miR dynamics following surgical excision. 
However, care should be exercised with respect to the design 
and timing of future postoperative plasma studies as analyses in 
close temporal proximity to surgical excision may obscure dif-
ferences in miR trends. Ideally, future studies will incorporate 
additional postsurgical blood draws at different time points to 
more comprehensively analyze these trends. Likewise, analysis 
of distant metastatic samples does not appear to have large 
variations in miR patterns following surgical resection, which 
may be attributed, in part, to a sustained inflammatory response 
postoperatively. Future studies may specifically tailor their 
design to include individuals limited to locoregional disease 
when performing plasma-based approaches and consider the 
use of tissue-based approaches for those with distant meta-
static disease to potentially avoid this discrepancy. Ultimately, 
further characterization of the impact of staging and temporal 
response on postsurgical inflammation is necessary to accu-
rately understand plasma miR dynamics in melanoma.
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